The Behring unit, which makes up around 70% of CSL's revenue, recorded a 15% jump in immunoglobulin sales to $3.17 billion, ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Collegiate esports company CSL Esports has become a new division of sports marketing, media, and technology company Playfly Sports. As a result of the deal, CSL Esports will rebrand to Playfly Esports ...

Carlisle Companies Incorporated operates as a manufacturer and supplier of building envelope products and solutions in the United States, Europe, North America, Asia and the Middle East, Africa ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

CSL Ltd (ASX: CSL) and ResMed Inc (ASX: RMD) shares are popular blue chip options for investors. But are they in the buy zone right now? Let's take a look at what one leading broker is saying ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

Jefferies analyst David Stanton maintained a Buy rating on CSL (CMXHF – Research Report) on January 17 and set a price target of A$341.00. The company’s shares closed last Friday at $163.15.

Learn More Now could be the time to pounce on CSL Ltd (ASX: CSL ... in its core Immunoglobulin (IG) market, its Vifor acquisition encountering the entry of generics quicker than anticipated ...